Business
Integra LifeSciences Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides 2022 Financial Guidance
PRINCETON, N.J., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth
About this update from Integra Lifesciences Holdings Corporation
[{"type":"text","content":"PRINCETON, N.J., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2021, consistent with its preliminary revenue results announced on January 11, 2022. Fourth Quarter 2021 Reported revenues were $405.5 million, representing an increase of 4.3% on a reported basis and an increase of 8.3% on an organic basis compared to the fourth quarter 2020. GAAP earnings per diluted share were $0.53, compared to $1.09 in the fourth quarter 2020.Adjusted earnings per diluted share were $0.84, flat compared to the fourth quarter of 2020. Full-Year 2021 Reported revenues were $1,542.4 million representing an increase of 12.4% on a reported basis and an increase of 14.2% on an organic basis compared to full-year 2020. GAAP earnings per diluted share were $1.98, compared to $1.57 in 2020. Adjusted earnings per diluted share were $3.18, compared to $2.45 in 2020. Key Accomplishments in 2021 Divested the Extremity Orthopedics business and acquired ACell to expand the regenerative tissue portfolio. Completed the substantive manufacturing transfer of all Codman neurosurgical products. Launched CereLink® ICP Monitor in Europe and the U.S. Initiated phased clinical launch for the Aurora® Surgiscope® for minimally invasive neurosurgery and MIRROR registry for intracerebral brain hemorrhage. Filed SurgiMend® PMA and completed panel meeting with FDA Advisory Committee and are currently working with FDA on the path forward for a specific indication for post-mastectomy breast reconstruction. Published results of PriMatrix® multicenter study in diabetic foot ulcers demonstrating statistically and clinically significant results against standard of care. Marked the 25th anniversary of the U.S. approval of the Integra® Dermal Regeneration Template (IDRT) for the treatment of life-threatening burns. Recognized for the company's leadership in ‘2021 Best Company for Diversity’ and ‘Top 100 Healthcare Technology Company’ lists. Successfully executed CEO transition with the appointment of Jan De Witte. “Our 2021 financial performance and business achievements are a testament to our broad and differentiated product portfolio, and the resilience and commitment of our team members around the world, despite the ongoing effects of the global pa...